

## CLINICAL CAPSULES

## ICD Beats Amiodarone in Heart Failure

In a direct comparison of the two therapies developed specifically to prevent sudden cardiac death in patients with heart failure, only the implantable cardioverter defibrillator (ICD) succeeded in doing so. Conservatively programmed, shock-only, single-lead ICD therapy cut mortality by 23%; amiodarone had no effect on survival, said Gust H. Bardy, M.D., of the Seattle Institute for Cardiac Research, and associates.

The benefits of both therapies have remained uncertain, so 2,521 patients with heart failure were enrolled in the Sudden

Cardiac Death in Heart Failure Trial and followed for a median of 45 months. All received optimal conventional treatment. In addition, 845 were randomly assigned to receive amiodarone, 847 received placebo, and 829 received an ICD. The ICD was programmed to treat only rapid, sustained ventricular tachycardia or fibrillation.

Even though they found a 5% rate of acute device-related complications and a 9% rate of chronic complications, the survival benefit "outweighs any shortcomings of this approach," the researchers added (N. Engl. J. Med. 2005;352:225-37).

"We cannot emphasize too strongly that we evaluated only very conservatively programmed ICDs with a conservative detection algorithm and shock-only therapy ... considerable caution should be used in extrapolating our results to other approaches to ICD therapy," they noted.

**Thrombolysis-Induced Ocular Bleeding** Hemorrhage is a well-known complication of thrombolytic therapy, but possible involvement of the retina is less well known, said Riyaz A. Kaba, M.D., and associates at Hillingdon Hospital, Uxbridge, England.

They reported the case of a 66-year-old man who received thrombolytic therapy

when he presented with acute MI. Within a few hours, he had impaired vision in his left eye. Fundoscopic examination revealed subretinal hemorrhage, predominantly at the macular and posterior pole, and a large pool of blood between the retina and the vitreous base (Lancet 2005;365:330).

The vitreous hemorrhage brought on by thrombolysis persisted at 3-month follow-up, and vision in the patient's left eye remained impaired.

**Electrical Stimulation After Stroke**

Early, intensive electrical stimulation of the leg muscles to mimic normal walking aided recovery of walking ability after stroke, said Tiebin Yan, M.D., of the Hong Kong Polytechnic University, and associates.

Of 41 patients aged 45-85 years who had an acute unilateral stroke within the carotid artery system, 13 were randomly assigned to receive functional electrical stimulation of the quadriceps, hamstring, tibialis anterior, and medial gastrocnemius muscles in a sequence that mimicked a normal gait. The 30-minute stimulation sessions were given 5 days a week for 3 weeks, starting within 3 days after transfer from an acute care facility. Another 13 patients who had no electrical muscle stimulation formed the control group, while 15 patients who had sham stimulation sessions formed the placebo group. All also received standard daily rehabilitative physiotherapy and occupational therapy, the researchers said (Stroke 2005;36:80-5).

Nearly 85% of the treatment group, compared with only 53% of the sham treatment group and 46% of the control group, recovered their walking ability and returned home to live independently. The treated patients also showed less muscle spasticity than those in the other groups.

**Deep Sternal Wound Infection Is Risky**

The detrimental effects of deep sternal wound infection after coronary artery bypass grafting (CABG) extend well beyond the first 30 days, when patients typically appear to have fully recovered. This complication raises the risk of death threefold over the next 10 years at least, reported Ioannis K. Toumpoulis, M.D., of Columbia University, New York, and associates.

The long-term effects of deep sternal wound infection have not been well studied. To assess the impact of the infection on long-term survival, the researchers reviewed 3,760 consecutive cases of CABG performed at St. Luke's-Roosevelt Hospital Center from 1992 to 2002. Thirty-day mortality was the same in the 40 patients with deep sternal wound infection as in the unaffected patients.

But in patients who had developed the infection, overall mortality was markedly higher at 1 year (33.8%), 5 years (49.2%), and 10 years after CABG (59.4%) than it was in patients who had not developed deep sternal wound infection (6.4%, 16.8%, and 32.7%, respectively). The exact mechanism by which this complication continues to affect patient health for years after they have "recovered" remains unknown, the investigators noted (Chest 2005;127:464-71).

All patients who develop deep sternal wound infection should be followed carefully and monitored frequently thereafter, they added.

—Mary Ann Moon



Rx Only

**Brief Summary of Prescribing Information.**

For complete details, please see full Prescribing Information for NAMENDA.

**INDICATIONS AND USAGE**

NAMENDA (memantine hydrochloride) is indicated for the treatment of moderate to severe dementia of the Alzheimer's type.

**CONTRAINDICATIONS**

NAMENDA (memantine hydrochloride) is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation.

**PRECAUTIONS**

**Information for Patients and Caregivers:** Caregivers should be instructed in the recommended administration (twice per day for doses above 5 mg) and dose escalation (minimum interval of one week between dose increases).

**Neurological Conditions**

Seizures: NAMENDA has not been systematically evaluated in patients with a seizure disorder. In clinical trials of NAMENDA, seizures occurred in 0.2% of patients treated with NAMENDA and 0.5% of patients treated with placebo.

**Genitourinary Conditions**

Conditions that raise urine pH may decrease the urinary elimination of memantine resulting in increased plasma levels of memantine.

**Special Populations****Hepatic Impairment**

NAMENDA undergoes partial hepatic metabolism, but the major fraction of a dose (57-82%) is excreted unchanged in urine. The pharmacokinetics of memantine in patients with hepatic impairment have not been investigated, but would be expected to be only modestly affected.

**Renal Impairment**

There are inadequate data available in patients with mild, moderate, and severe renal impairment but it is likely that patients with moderate renal impairment will have higher exposure than normal subjects. Dose reduction in these patients should be considered. The use of NAMENDA in patients with severe renal impairment is not recommended.

**Drug-Drug Interactions**

**N-methyl-D-aspartate (NMDA) antagonists:** The combined use of NAMENDA with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution.

**Effects of NAMENDA on substrates of microsomal enzymes:** *In vitro* studies conducted with marker substrates of CYP450 enzymes (CYP1A2, -2A6, -2C9, -2D6, -2E1, -3A4) showed minimal inhibition of these enzymes by memantine. No pharmacokinetic interactions with drugs metabolized by these enzymes are expected.

**Effects of inhibitors and/or substrates of microsomal enzymes on NAMENDA:** Memantine is predominantly renally eliminated, and drugs that are substrates and/or inhibitors of the CYP450 system are not expected to alter the metabolism of memantine.

**Acetylcholinesterase (AChE) inhibitors:** Coadministration of NAMENDA with the AChE inhibitor donepezil HCl did not affect the pharmacokinetics of either compound. In a 24-week controlled clinical study in patients with moderate to severe Alzheimer's disease, the adverse event profile observed with a combination of memantine and donepezil was similar to that of donepezil alone.

**Drugs eliminated via renal mechanisms:** Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. However, coadministration of NAMENDA and HCTZ/TA did not affect the bioavailability of either memantine or TA, and the bioavailability of HCTZ decreased by 20%.

**Drugs that make the urine alkaline:** The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate), and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). Hence, memantine should be used with caution under these conditions.

**Carcinogenesis, Mutagenesis and Impairment of Fertility**

There was no evidence of carcinogenicity in a 113-week oral study in mice at doses up to 40 mg/kg/day (10 times the maximum recommended human dose [MRHD] on a mg/m<sup>2</sup> basis). There was also no evidence of carcinogenicity in rats orally dosed at up to 40 mg/kg/day for 71 weeks followed by 20 mg/kg/day (20 and 10 times the MRHD on a mg/m<sup>2</sup> basis, respectively) through 128 weeks.

Memantine produced no evidence of genotoxic potential when evaluated in the *in vitro* S. typhimurium or E. coli reverse mutation assay, an *in vitro* chromosomal aberration test in human lymphocytes, an *in vivo* cytogenetics assay for chromosome damage in rats, and the *in vivo* mouse micronucleus assay. The results were equivocal in an *in vitro* gene mutation assay using Chinese hamster V79 cells.

No impairment of fertility or reproductive performance was seen in rats administered up to 18 mg/kg/day (9 times the MRHD on a mg/m<sup>2</sup> basis) orally from 14 days prior to mating through gestation and lactation in females, or for 60 days prior to mating in males.

**Pregnancy**

Pregnancy Category B: Memantine given orally to pregnant rats and pregnant rabbits during the period of organogenesis was not teratogenic up to the highest doses tested (18 mg/kg/day in rats and 30 mg/kg/day in rabbits, which are 9 and 30 times, respectively, the maximum recommended human dose [MRHD] on a mg/m<sup>2</sup> basis).

Slight maternal toxicity, decreased pup weights and an increased incidence of nonossified cervical vertebrae were seen at an oral dose of 18 mg/kg/day in a study in which rats were given oral memantine beginning pre-mating and continuing through the postpartum period. Slight maternal

toxicity and decreased pup weights were also seen at this dose in a study in which rats were treated from day 15 of gestation through the postpartum period. The no-effect dose for these effects was 6 mg/kg, which is 3 times the MRHD on a mg/m<sup>2</sup> basis.

There are no adequate and well-controlled studies of memantine in pregnant women. Memantine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

**Nursing Mothers**

It is not known whether memantine is excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when memantine is administered to a nursing mother.

**Pediatric Use**

There are no adequate and well-controlled trials documenting the safety and efficacy of memantine in any illness occurring in children.

**ADVERSE REACTIONS**

The experience described in this section derives from studies in patients with Alzheimer's disease and vascular dementia.

**Adverse Events Leading to Discontinuation:** In placebo-controlled trials in which dementia patients received doses of NAMENDA up to 20 mg/day, the likelihood of discontinuation because of an adverse event was the same in the NAMENDA group as in the placebo group. No individual adverse event was associated with the discontinuation of treatment in 1% or more of NAMENDA-treated patients and at a rate greater than placebo.

**Adverse Events Reported in Controlled Trials:** The reported adverse events in NAMENDA (memantine hydrochloride) trials reflect experience gained under closely monitored conditions in a highly selected patient population. In actual practice or in other clinical trials, these frequency estimates may not apply, as the conditions of use, reporting behavior and the types of patients treated may differ. Table 1 lists treatment-emergent signs and symptoms that were reported in at least 2% of patients in placebo-controlled dementia trials and for which the rate of occurrence was greater for patients treated with NAMENDA than for those treated with placebo. No adverse event occurred at a frequency of at least 5% and twice the placebo rate.

Table 1: Adverse Events Reported in Controlled Clinical Trials in at Least 2% of Patients Receiving NAMENDA and at a Higher Frequency than Placebo-Treated Patients.

Body System Adverse Event	Placebo (N = 922) %	NAMENDA (N = 940) %
Body as a Whole		
Fatigue	1	2
Pain	1	3
Cardiovascular System		
Hypertension	2	4
Central and Peripheral Nervous System		
Dizziness	5	7
Headache	3	6
Gastrointestinal System		
Constipation	3	5
Vomiting	2	3
Musculoskeletal System		
Back pain	2	3
Psychiatric Disorders		
Confusion	5	6
Somnolence	2	3
Hallucination	2	3
Respiratory System		
Coughing	3	4
Dyspnea	1	2

Other adverse events occurring with an incidence of at least 2% in NAMENDA-treated patients but at a greater or equal rate on placebo were agitation, fall, inflated injury, urinary incontinence, diarrhea, bronchitis, insomnia, urinary tract infection, influenza-like symptoms, gait abnormal, depression, upper respiratory tract infection, anxiety, peripheral edema, nausea, anorexia, and arthralgia.

The overall profile of adverse events and the incidence rates for individual adverse events in the subpopulation of patients with moderate to severe Alzheimer's disease were not different from the profile and incidence rates described above for the overall dementia population.

**Vital Sign Changes:** NAMENDA and placebo groups were compared with respect to (1) mean change from baseline in vital signs (pulse, systolic blood pressure, diastolic blood pressure, and weight) and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. There were no clinically important changes in vital signs in patients treated with NAMENDA. A comparison of supine and standing vital sign measures for NAMENDA and placebo in elderly normal subjects indicated that NAMENDA treatment is not associated with orthostatic changes.

**Laboratory Changes:** NAMENDA and placebo groups were compared with respect to (1) mean change from baseline in various serum chemistry, hematology, and urinalysis variables and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed no clinically important changes in laboratory test parameters associated with NAMENDA treatment.

**ECG Changes:** NAMENDA and placebo groups were compared with respect to (1) mean change from baseline in various ECG parameters and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed no clinically important changes in ECG parameters associated with NAMENDA treatment.

**Other Adverse Events Observed During Clinical Trials**

NAMENDA has been administered to approximately 1350 patients with dementia, of whom more than 1200 received the maximum recommended dose of 20 mg/day. Patients received NAMENDA treatment for periods of up to 884 days, with 862 patients receiving at least 24 weeks of treatment and 387 patients receiving 48 weeks or more of treatment.

Treatment emergent signs and symptoms that occurred during 8 controlled

clinical trials and 4 open-label trials were recorded as adverse events by the clinical investigators using terminology of their own choosing. To provide an overall estimate of the proportion of individuals having similar types of events, the events were grouped into a smaller number of standardized categories using WHO terminology, and event frequencies were calculated across all studies.

All adverse events occurring in at least two patients are included, except for those already listed in Table 1, WHO terms too general to be informative, minor symptoms or events unlikely to be drug-caused, e.g., because they are common in the study population. Events are classified by body system and listed using the following definitions: frequent adverse events – those occurring in at least 1/100 patients; infrequent adverse events – those occurring in 1/100 to 1/1000 patients. These adverse events are not necessarily related to NAMENDA treatment and in most cases were observed at a similar frequency in placebo-treated patients in the controlled studies.

**Body as a Whole:** Frequent: syncope. Infrequent: hypothermia, allergic reaction.

**Cardiovascular System:** Frequent: cardiac failure. Infrequent: angina pectoris, bradycardia, myocardial infarction, thrombophlebitis, atrial fibrillation, hypotension, cardiac arrest, postural hypotension, pulmonary embolism, pulmonary edema.

**Central and Peripheral Nervous System:** Frequent: transient ischemic attack, cerebrovascular accident, vertigo, ataxia, hypokinesia. Infrequent: paresthesia, convulsions, extrapyramidal disorder, hypertonia, tremor, aphasia, hypoesthesia, abnormal coordination, hemiplegia, hyperkinesia, involuntary muscle contractions, stupor, cerebral hemorrhage, neuralgia, ptosis, neuropathy.

**Gastrointestinal System:** Infrequent: gastroenteritis, diverticulitis, gastrointestinal hemorrhage, melena, esophageal ulceration.

**Hemic and Lymphatic Disorders:** Frequent: anemia. Infrequent: leukopenia.

**Metabolic and Nutritional Disorders:** Frequent: increased alkaline phosphatase, decreased weight. Infrequent: dehydration, hyponatremia, aggravated diabetes mellitus.

**Psychiatric Disorders:** Frequent: aggressive reaction. Infrequent: delusion, personality disorder, emotional lability, nervousness, sleep disorder, libido increased, psychosis, amnesia, apathy, paranoid reaction, thinking abnormal, crying abnormal, appetite increased, paranoia, delirium, depersonalization, neurosis, suicide attempt.

**Respiratory System:** Frequent: pneumonia. Infrequent: apnea, asthma, hemoptysis.

**Skin and Appendages:** Frequent: rash. Infrequent: skin ulceration, pruritus, cellulitis, eczema, dermatitis, erythematous rash, alopecia, urticaria.

**Special Senses:** Frequent: cataract, conjunctivitis. Infrequent: macula lutea degeneration, decreased visual acuity, decreased hearing, tinnitus, blepharitis, blurred vision, corneal opacity, glaucoma, conjunctival hemorrhage, eye pain, retinal hemorrhage, xerophthalmia, diplopia, abnormal lacrimation, myopia, retinal detachment.

**Urinary System:** Frequent: frequent micturition. Infrequent: dysuria, hematuria, urinary retention.

**ADVERSE EVENTS FROM OTHER SOURCES**

Memantine has been commercially available outside the United States since 1982, and has been evaluated in clinical trials including trials in patients with neuropathic pain, Parkinson's disease, organic brain syndrome, and spasticity. The following adverse events of possible importance for which there is inadequate data to determine the causal relationship have been reported to be temporally associated with memantine treatment in more than one patient and are not described elsewhere in labeling: acne, bone fracture, carpal tunnel syndrome, claudication, hyperlipidemia, impotence, otitis media, thrombocytopenia.

**ANIMAL TOXICOLOGY**

Memantine induced neuronal lesions (vacuolation and necrosis) in the multipolar and pyramidal cells in cortical layers II and IV of the posterior cingulate and retrosplenial neocortices in rats, similar to those which are known to occur in rodents administered other NMDA receptor antagonists. Lesions were seen after a single dose of memantine. In a study in which rats were given daily oral doses of memantine for 14 days, the no-effect dose for neuronal necrosis was 6 times the maximum recommended human dose on a mg/m<sup>2</sup> basis. The potential for induction of central neuronal vacuolation and necrosis by NMDA receptor antagonists in humans is unknown.

**DRUG ABUSE AND DEPENDENCE**

**Controlled Substance Class:** Memantine HCl is not a controlled substance.

**Physical and Psychological Dependence:** Memantine HCl is a low to moderate affinity uncompetitive NMDA antagonist that did not produce any evidence of drug-seeking behavior or withdrawal symptoms upon discontinuation in 2,504 patients who participated in clinical trials at therapeutic doses. Post marketing data, outside the U.S., retrospectively collected, has provided no evidence of drug abuse or dependence.

**OVERDOSAGE**

Because strategies for the management of overdose are continually evolving, it is advisable to contact a poison control center to determine the latest recommendations for the management of an overdose of any drug. As in any cases of overdose, general supportive measures should be utilized, and treatment should be symptomatic. Elimination of memantine can be enhanced by acidification of urine. In a documented case of an overdose with up to 400 mg of memantine, the patient experienced restlessness, psychosis, visual hallucinations, somnolence, stupor and loss of consciousness. The patient recovered without permanent sequelae.

Forest Pharmaceuticals, Inc.

Pharmaceuticals • Therapeutics • Healthcare • Ethicare • Managed Care • Specialty Sales

Licensed from Merz Pharmaceuticals GmbH

Rev. 6/04

© 2004 Forest Laboratories, Inc.